Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Oliver Sailer

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Pharmaceutical Statistics|February 24, 2017
Probability of success for phase III after exploratory biomarker analysis in phase IIHeiko Götte, Marietta Kirchner, Martin Oliver Sailer
CPT: Pharmacometrics & Systems Pharmacology|August 30, 2023
Pharmacometrics enhanced Bayesian borrowing approach to improve clinical trial efficiency: Case of empagliflozin in type 2 diabetesLucie Fayette, Martin Oliver Sailer, Alejandro Perez-Pitarch
Statistics in Medicine|April 25, 2017
Simulation-based adjustment after exploratory biomarker subgroup selection in phase IIHeiko Götte, Marietta Kirchner, Martin Oliver Sailer, et al.
Biometrics|April 29, 2016
On confidence intervals for the hazard ratio in randomized clinical trialsDan-Yu Lin, Luyan Dai, Gang Cheng, et al.
Journal of Biopharmaceutical Statistics|March 8, 2023
Propensity score stratified MAP prior and posterior inference for incorporating information across multiple potentially heterogeneous data sourcesAngela Yaqian Zhu, Dooti Roy, Zheng Zhu, et al.
Pharmaceutical Statistics|October 3, 2023
Duration of and time to response in oncology clinical trials from the perspective of the estimand frameworkHans-Jochen Weber, Stephen Corson, Jiang Li, et al.
Therapeutic Innovation & Regulatory Science|October 7, 2024
Pharmacometrics-Enhanced Bayesian Borrowing for Pediatric Extrapolation - A Case Study of the DINAMO TrialMartin Oliver Sailer, Dietmar Neubacher, Curtis Johnston, et al.
The Lancet. Oncology|November 23, 2015
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trialAndreas du Bois, Gunnar Kristensen, Isabelle Ray-Coquard, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Pharmaceutical Statistics|February 24, 2017
Probability of success for phase III after exploratory biomarker analysis in phase IIHeiko Götte, Marietta Kirchner, Martin Oliver Sailer
CPT: Pharmacometrics & Systems Pharmacology|August 30, 2023
Pharmacometrics enhanced Bayesian borrowing approach to improve clinical trial efficiency: Case of empagliflozin in type 2 diabetesLucie Fayette, Martin Oliver Sailer, Alejandro Perez-Pitarch
Statistics in Medicine|April 25, 2017
Simulation-based adjustment after exploratory biomarker subgroup selection in phase IIHeiko Götte, Marietta Kirchner, Martin Oliver Sailer, et al.
Biometrics|April 29, 2016
On confidence intervals for the hazard ratio in randomized clinical trialsDan-Yu Lin, Luyan Dai, Gang Cheng, et al.
Journal of Biopharmaceutical Statistics|March 8, 2023
Propensity score stratified MAP prior and posterior inference for incorporating information across multiple potentially heterogeneous data sourcesAngela Yaqian Zhu, Dooti Roy, Zheng Zhu, et al.
Pharmaceutical Statistics|October 3, 2023
Duration of and time to response in oncology clinical trials from the perspective of the estimand frameworkHans-Jochen Weber, Stephen Corson, Jiang Li, et al.
Therapeutic Innovation & Regulatory Science|October 7, 2024
Pharmacometrics-Enhanced Bayesian Borrowing for Pediatric Extrapolation - A Case Study of the DINAMO TrialMartin Oliver Sailer, Dietmar Neubacher, Curtis Johnston, et al.
The Lancet. Oncology|November 23, 2015
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trialAndreas du Bois, Gunnar Kristensen, Isabelle Ray-Coquard, et al.
Pageof 1